This inquiry was established to to identify and address any vulnerabilities that had or potentially could emerge, in relation to vaccine and vaccine related fraud and security, and provide the Australian public with confidence in the integrity of the COVID-19 vaccination program.

This report argues that, despite receiving billions in public funding, a number of pharmaceutical companies are continuing to put their own business interests before their human rights responsibilities by creating barriers to fair access to their COVID-19 vaccines through their decisions not to share intellectual property and technology.

This interim report reviews the performance of New Zealand's medicines procurement agency, Pharmac.

Australia’s National Immunisation Program and its supporting infrastructure has been one of the major reasons the country has been so successful in vaccination policy. This report argues that ensuring Australia’s funding levels are sufficient, that our evaluation and decision support frameworks are best practice, and that government procurement processes are focussed on both the short-...

This report examines the opportunities to deliver better health care for Australians through our regulatory and health technology assessment process for both medicines and technologies.